News from the 7th Annual Scientific Meeting of the Cardiorenal Forum

This year’s 7th Annual Scientific Meeting of the Cardiorenal Forum looked at diabetes and other co-morbidities in relation to cardiorenal disease. The meeting was held at the Royal Institute of British Architects, London, October 5th 2012, and endorsed by the Renal Association and the British Society for Heart Failure. Michael Pope and Hugh McIntyre report on its highlights.

Introduction

As doctors and scientists we are accustomed to breaking down problems and simplifying complex pathophysiology in order to focus our management and identify possible targets for future therapies. The pathophysiology of cardiorenal disease is no different but, as yet, attempts to elucidate the complex interaction between heart and kidneys has failed.

Although cardiac and renal disease are often diagnosed together, it is clear that a straightforward causal relationship does not exist. Disease in either serves as a risk factor for disease in the other and perpetuates the progression of that disease, but why this is so is unclear. Whilst the renin-angiotensin-aldosterone system (RAAS) certainly plays its part and therapeutic strategies targeted at inhibiting this system have been successful, much of the pathophysiology remains unexplained.

The Cardiorenal Forum was created in response to a realisation that success in the management of cardiorenal disease would only come about by a change of perspective that explored cardiological and nephrological pathologies together. The forum’s 7th Annual Scientific meeting focussed on diabetes and other comorbidities, exploring how these may provide targets for future therapeutic interventions.

Inflammation

There is increasing evidence that inflammation plays an important role in the pathophysiology of both renal and cardiac disease. Dr Paul Audhya (Reata Pharmaceuticals, Irving, Texas, USA) described the inflammatory cascade as a “deterministic chaos”, meaning that there is no one pathway with multiple steps making up the inflammatory process, but rather a multitude of highly complex pathways, none of which are distinct from each other. These pathways interact in numerous ways, and with effects which can be impossible to identify, or ascribe to one clear molecular or chemical process. The process cannot easily be broken down into its constituent parts, or manipulated with pharmacological interventions.

Numerous markers of inflammation have been identified as playing a part in cardiac and renal disease, including tumour necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), human soluble TNF-receptor type 1 (sTNF-R1), and C-reactive protein (CRP). Inflammation is an early component of endothelial activation, involved in atheromatous plaque formation, as well as both renal and myocardial fibrosis and remodelling resulting in heart failure and reduced glomerular filtration. However, attempts at targeting these inflammatory pathways with drug therapies have so far been unsuccessful.

Randomised controlled trials of TNF blockers in heart failure were stopped early due to fears of worsening outcomes. Beyond their well-recognised effect on low-density lipoprotein (LDL) cholesterol, statins have been shown to decrease oxidative stress and subsequently decrease TNF-α, IL-1β, interleukin 6 (IL-6), soluble vascular-cell adhesion molecule-1 (sVCAM-1) and von Willebrand factor (vWF) resulting in a reduction of number of inflammatory cells and stabilisation of atheromatous plaques. Despite this clearly anti-inflammatory effect, they have no benefit in heart failure.

A novel anti-oxidant derivative of oleanolic acid, bardoxolone, which exerts its anti-inflammatory effects via inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was shown to significantly increase estimated glomerular filtration rate (GFR), however, in patients with moderate-to-severe chronic kidney disease (CKD) and type 2 diabetes mellitus in the BEAM study (Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes). Unfortunately the phase 3 BEACON trial of bardoxolone methyl in patients with stage 4 CKD and type 2 diabetes has recently been terminated early, due to excess adverse events and mortality in the treatment arm.

Diabetes

The microvascular and macrovascular complications of diabetes are well known, as are their effects on renal and cardiovascular disease. However, although at first sight this relationship appears clear – hyperglycaemia resulting in endothelial damage, inflammation, fibrosis, and subsequent renal dysfunction and atheromatous plaque formation – the truth is far more chaotic. The microvascular complications are considered specific to diabetes, but are not an inevitable consequence of hyperglycaemia. In type 1 diabetes, retinopathy is largely related to glycaemic control, but nephropathy is not.

It is observed that patients either suffer nephropathy or they don’t, and whilst a genetic cause for this has been postulated, no responsible genes have been identified. Similarly, type 2 diabetes is increasingly recognised as not simply a disease of glucose regulation but rather a systemic disease of metabolism. Macrovascular complications are not specific to diabetes, but type 2 diabetes is an independent risk factor and is the most common cause of end stage renal disease in the UK.
MEETING REPORT

Professor Steve Bain (Swansea NHS Trust and University of Wales) drew attention to the “golden years cohort”. This group of patients with type 1 diabetes, treated with insulin for 50–70 years, had an average glycated haemoglobin (Hba1c) of 7.6% and yet are observed to suffer no complications of their diabetes. Other characteristics of this group are that they are generally lean, require low insulin doses, and have elevated high-density lipoproteins (HDL), in stark contrast to the characteristics of the metabolic syndrome of which type 2 diabetes is a part.

Remarkably, 35.7% of these patients have micro or macroalbuminuria. Micro- and subsequently macroalbuminuria are considered the first detectable signs of renal dysfunction in diabetes and predate the deterioration in GFR. Screening for these is therefore considered important to allow instigation of therapies such as angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists in order to delay the decrease in GFR.

However, the observation of an abnormal albumin/creatinine ratio in the golden years cohort, despite a low risk of significant renal dysfunction and the fact that patients often have hypertension and microalbuminuria at the time of diagnosis of diabetes, may suggest a further pathological entity in addition to the characteristics of the metabolic syndrome of which type 2 diabetes is a part.

Aldosterone

As already highlighted, the RAAS (figure 1) is really the only significant pathophysiological pathway in cardiorenal disease that we have been able to successfully manipulate for therapeutic gain. However, it is becoming increasingly clear that we do not fully understand the effect of upregulation of this system and the pathophysiological effect of increased circulating aldosterone is clearly far beyond that of fluid and electrolyte balance. Similarly, we’ve come to appreciate that aldosterone production is not purely an effect of circulating angiotensin II. Indeed, ACE inhibitors are known to cause an initial drop in both angiotensin II and aldosterone, but this rebounds with a slow increase in aldosterone.

This may in part be the result of aldosterone synthase induction in the renal cortex, which as well as occurring in response to angiotensin II, is also potentiated by a low sodium intake, high blood sugars and possibly high blood lipids. Equally, we know that aldosterone has both paracrine and autocrine effects beyond its well-recognised endocrine actions when produced by endothelial cells, vascular smooth muscle, blood pressure control areas of the brain, and the renal cortex. Beyond the well-studied endocrine actions, which remain unclear, there is emerging evidence of an association between aldosterone and mineral bone disorders.

Recent efforts to elucidate the true pathological effects of aldosterone increasingly focus on inflammation and fibrosis. We know from animal studies that an infusion of aldosterone will promote an inflammatory response with increased circulating pro-inflammatory cytokines, formation of reactive oxygen species (the harbingers of oxidative stress), and growth factors such as the ubiquitous transforming growth factor beta (TGF–β). This results in fibroblast proliferation and activation, increased collagen production, and fibrosis.

That this has such significant repercussions for cardiac and renal disease is not surprising. On the vasculature, this causes arteriosclerosis and stiffening, exposing the myocardium to grossly abnormal loading conditions leading to left ventricular hypertrophy. On the heart, it causes fibrotic remodelling thereby adversely affecting myocardial contractility. On the kidneys, it causes glomerulosclerosis and renal scarring with progressive loss of nephrons and fall in GFR. As this reduction in GFR progresses, the normal relationship between high extracellular volume and low aldosterone becomes distorted and in patients with end stage kidney disease on dialysis, levels of circulating aldosterone are grossly elevated. This, perhaps, goes some way to explaining the accelerated vascular and cardiac pathology observed in this group of patients and why the leading causes of death in end stage renal disease are heart failure and sudden cardiac death.

Dr John Townend (University Hospital Birmingham NHS Foundation Trust) pointed...
out that the heart, although obviously a muscle, could also be viewed as a “collagenous skeleton in which myocytes exist”, with an approximately 3:1 ratio of fibroblasts to myocytes and complete turnover of cardiac collagen every three to four weeks. Interruption of this dynamic process could explain the strong benefits of mineralocorticoid receptor (MR) antagonists in heart failure demonstrated by both the RALES (Randomised Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart Failure) studies. Indeed, further studies have shown spironolactone to decrease left ventricular mass index, as well as reduce arterial stiffness and increase aortic distensibility, even in patients who were not hypertensive and had a normal left ventricular mass at baseline.

The fact that mineralocorticoid receptors are found in the preglomerular vasculature, mesangial cells, fibroblasts and adipocytes – key areas in regulating fibrosis – again highlights the significance of aldosterone in CKD. In recognising the importance of aldosterone for driving progression of kidney disease through renal remodelling, should we be rethinking our approach to spironolactone in this group of patients? Since we know that ACE inhibitors slow the progression of CKD, might MR antagonists be shown to have this effect too, and would it necessitate a reappraisal of our approach to hyperkalaemia?

Michael Pope
FY2 Doctor
Queen Alexandra Hospital, Portsmouth,
(mtbpope@doctors.org.uk)
Hugh McIntyre
Consultant Cardiologist
Conquest Hospital, Hastings